$3.83
+0.15 (+4.08%)
Open$3.63
Previous Close$3.68
Day High$3.91
Day Low$3.63
52W High$71.50
52W Low$3.12
Volume—
Avg Volume67.4K
Market Cap6.11M
P/E Ratio—
EPS$-41.82
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+145.4% upside
Current
$3.83
$3.83
Target
$9.40
$9.40
$5.45
$9.40 avg
$11.97
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 2.82M | 2.16M | 1.98M |
| Net Income | -84,045,128 | -609,365 | -497,914 |
| Profit Margin | -2,980.4% | -28.2% | -25.1% |
| EBITDA | -83,665,754 | -937,252 | -843,277 |
| Free Cash Flow | — | -606,690 | -515,846 |
| Rev Growth | +100.0% | +2.0% | +14.6% |
| Debt/Equity | — | 0.62 | 0.60 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $254.31 | +0.38% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $360.55 | +0.62% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.33 | -1.21% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $499.65 | +1.69% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $631.81 | -0.17% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $293.52 | +0.74% | 69.3 | 39.97B |